NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的阿霉素市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Doxorubicin Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1010201
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的阿霉素市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Doxorubicin Market 2021-2025
出版日期: 2021年06月08日內容資訊: 英文 50 Pages
簡介

在中國市場的阿霉素的銷售量,從2016年到2020年年年增加。尤其是,2019年的銷售額達8億5,500萬人民幣,以與前一年同期比較增加69.75%。2020年,由於COVID-19對中國的醫院的診斷及治療服務全體的影響,中國市場中阿霉素的銷售量的成長率降低,不過,2020年的銷售量依然達到約10億人民幣。中國市場中阿霉素的銷售量,從2016年到2020年期間以38.6%的年複合成長率成長。

本報告提供中國的阿霉素市場的相關調查,市場規模和預測,價格,成長要素和機會等市場發展的影響因素分析,競爭情形,主要製造商/產品的簡介等資訊。

目錄

第1章 阿霉素的相關概念

  • 阿霉素的適應症
  • 中國的阿霉素的開發
  • 中國的阿霉素的政府核准
  • COVID-19對中國的阿霉素銷售的影響

第2章 中國的阿霉素銷售(2016-2020)

  • 阿霉素的銷售額
    • 總銷售額
    • 各區域銷銷售額
  • 阿霉素的銷售量
    • 總銷售量
    • 各地區銷售量
  • 中國的各劑型阿霉素銷售(2016-2020)
    • 注射
    • 微脂體注射

第3章 中國的主要阿霉素製造商分析(2016-2020)

  • 主要的阿霉素製造商市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售量市場佔有率調查
  • CSPC Ouyi Pharmaceutical Co., Ltd.
    • 企業簡介
    • Duomeisu(CSPC Ouyi Pharmaceutical Co., Ltd.的阿霉素)在中國的銷售
  • Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.
    • 企業簡介
    • Libaoduo(Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.的阿霉素)在中國的銷售
  • Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
    • 企業簡介
    • Lixing(Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.的阿霉素)在中國的銷售
  • Shenzhen Main Luck Pharmaceuticals Inc.
    • 企業簡介
    • Shenzhen Main Luck Pharmaceuticals Inc.的阿霉素在中國的銷售
  • Shanxi Powerdone Pharmaceutics Co., Ltd.
    • 企業簡介
    • Shanxi Powerdone Pharmaceutics Co., Ltd.的阿霉素在中國的銷售

第4章 中國的各製造商阿霉素的價格(2020年∼2021年)

  • CSPC Ouyi Pharmaceutical Co., Ltd. (Duomeisu)
  • Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd. (Libaoduo)
  • Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. (Lixing)
  • Shenzhen Main Luck Pharmaceuticals Inc.
  • Shanxi Powerdone Pharmaceutics Co., Ltd.

第5章 中國的阿霉素市場預測(2021-2025)

  • 中國的阿霉素市場開發的有影響力的要素
    • COVID-19對中國的阿霉素市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106529

Doxorubicin belongs to the anthracycline class (Anthracycline) antibiotics, which can inhibit the synthesis of RNA and DNA. It has a strong inhibitory effect on RNA and has a broad anti-tumor spectrum. It has an effect on a variety of tumors. Doxorubicin was developed by Alza Corporation of the United States. According to CRI's market research, as of the end of 2020, the original Doxorubicin drug has not been listed in China, but many companies have obtained approval for the listing of generic drugs in China and have been included in the China National Medical Insurance Category A catalog. By 2020, there were 8 manufacturers in the Chinese Doxorubicin market, of which CSPC Ouyi Pharmaceutical Co., Ltd. was the main manufacturer.

According to CRI's market research, the sales value of Doxorubicin in the Chinese market has increased year by year from 2016 to 2020. Especially, the sales of Doxorubicin in the Chinese market reached CNY 855 million in 2019, a year-on-year increase of 69.75%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin's sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020. The CAGR of Doxorubicin's sales value in the Chinese market is 38.60% in 2016 to 2020.

CRI expects that with the increase of cancer patients in 2021-2025, the sales volume of Doxorubicin in the Chinese market will increase steadily. Doxorubicin liposome injection has the advantages of targeting, sustained release, and reduced toxicity. Based on these advantages, the sales volume and sales of Doxorubicin liposome injection will continue to increase. In addition, the alleviation of the COVID-19 epidemic will also cause the sales of Doxorubicin to show a recovery growth.

Topics Covered:

  • The impact of COVID-19 on China's Doxorubicin market
  • Sales value of China's Doxorubicin 2016-2020
  • Competitive landscape of China's Doxorubicin market
  • Prices of Doxorubicin in China
  • Prices of Doxorubicin in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Doxorubicin market
  • Prospect of China's Doxorubicin market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Doxorubicin

  • 1.1 Indications for Doxorubicin
  • 1.2 Development of Doxorubicin in China
  • 1.3 Governmental Approval of Doxorubicin in China
  • 1.4 The Impact of COVID-19 on Doxorubicin sales in China

2 Sales of Doxorubicin in China, 2016-2020

  • 2.1 Sales Value of Doxorubicin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Doxorubicin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Doxorubicin by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Liposome Injection

3 Analysis of Major Doxorubicin Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Doxorubicin Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 CSPC Ouyi Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Duomeisu (CSPC Ouyi Pharmaceutical Co., Ltd.'s Doxorubicin) in China
  • 3.3 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Libaoduo (Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.'s Doxorubicin) in China
  • 3.4 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Lixing (Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.'s Doxorubicin) in China
  • 3.5 Shenzhen Main Luck Pharmaceuticals Inc.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Shenzhen Main Luck Pharmaceuticals Inc.'s Doxorubicin in China
  • 3.6 Shanxi Powerdone Pharmaceutics Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Shanxi Powerdone Pharmaceutics Co., Ltd.'s Doxorubicin in China

4 Prices of Doxorubicin for Different Manufacturers in China, 2020-2021

  • 4.1 CSPC Ouyi Pharmaceutical Co., Ltd. (Duomeisu)
  • 4.2 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd. (Libaoduo)
  • 4.3 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. (Lixing)
  • 4.4 Shenzhen Main Luck Pharmaceuticals Inc.
  • 4.5 Shanxi Powerdone Pharmaceutics Co., Ltd.

5 Prospect of Chinese Doxorubicin Market, 2021-2025

  • 5.1 Influential Factors of Chinese Doxorubicin Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Doxorubicin Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Doxorubicin Injection Registration in China
  • Chart Patent Information About Doxorubicin Liposome Injection Registration in China
  • Chart Sales Value of Doxorubicin Injection over the World
  • Chart Sales Value of Doxorubicin Liposome Injection over the World
  • Chart Sales Value of Doxorubicin Injection in China, 2016-2020
  • Chart Sales Value of Doxorubicin Liposome Injection in China, 2016-2020
  • Chart Sales Value of Doxorubicin Injection in China by Region, 2016-2020
  • Chart Sales Value of Doxorubicin Liposome Injection in China by Region, 2016-2020
  • Chart Sales Volume of Doxorubicin Injection in China, 2016-2020
  • Chart Sales Volume of Doxorubicin Liposome Injection in China, 2016-2020
  • Chart Sales Volume of Doxorubicin Injection in China by Region, 2016-2020
  • Chart Sales Volume of Doxorubicin Liposome Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Doxorubicin Injection Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Doxorubicin Liposome Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of Duomeisu in China, 2016-2020
  • Chart Sales Value and Volume of Libaoduo in China, 2016-2020
  • Chart Sales Value and Volume of Lixing in China, 2016-2020
  • Chart Sales Value and Volume of Shenzhen Main Luck Pharmaceuticals Inc.'s Doxorubicin in China, 2016-2020
  • Chart Sales Value and Volume of Shanxi Powerdone Pharmaceutics Co., Ltd.'s Doxorubicin in China, 2016-2020
  • Chart Referential Prices of Duomeisu in China by Region, 2020-2021
  • Chart Referential Prices of Libaoduo in China by Region, 2020-2021
  • Chart Referential Prices of Lixing in China by Region, 2020-2021
  • Chart Referential Prices of Shenzhen Main Luck Pharmaceuticals Inc.'s Doxorubicin in China by Region, 2020-2021
  • Chart Referential Prices of Shanxi Powerdone Pharmaceutics Co., Ltd.'s Doxorubicin in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Doxorubicin Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Doxorubicin Liposome Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Doxorubicin Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Doxorubicin Liposome Injection in China, 2021-2025